GlaxoSmithKline (NYSE:GSK) was the target of unusually large options trading on Thursday. Investors purchased 29,143 call options on the stock. This represents an increase of 938% compared to the average daily volume of 2,808 call options.
Several analysts recently issued reports on the company. ValuEngine lowered GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Friday, May 4th. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Thursday, April 19th. Deutsche Bank reiterated a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, April 9th. BNP Paribas upgraded GlaxoSmithKline from a “neutral” rating to an “outperform” rating in a report on Wednesday, April 4th. Finally, Morgan Stanley upgraded GlaxoSmithKline from an “underweight” rating to an “equal weight” rating in a report on Thursday, March 22nd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $40.21.
Get GlaxoSmithKline alerts:
Several large investors have recently modified their holdings of the company. Renaissance Technologies LLC grew its position in shares of GlaxoSmithKline by 2.4% in the fourth quarter. Renaissance Technologies LLC now owns 9,668,300 shares of the pharmaceutical company’s stock valued at $342,935,000 after purchasing an additional 230,600 shares during the last quarter. Two Sigma Advisers LP grew its position in shares of GlaxoSmithKline by 55.5% in the fourth quarter. Two Sigma Advisers LP now owns 5,074,642 shares of the pharmaceutical company’s stock valued at $179,998,000 after purchasing an additional 1,811,400 shares during the last quarter. Northern Trust Corp grew its position in shares of GlaxoSmithKline by 10.6% in the first quarter. Northern Trust Corp now owns 3,206,664 shares of the pharmaceutical company’s stock valued at $125,284,000 after purchasing an additional 306,441 shares during the last quarter. Equity Investment Corp grew its position in shares of GlaxoSmithKline by 52.6% in the first quarter. Equity Investment Corp now owns 3,188,745 shares of the pharmaceutical company’s stock valued at $124,584,000 after purchasing an additional 1,098,625 shares during the last quarter. Finally, Two Sigma Investments LP grew its position in shares of GlaxoSmithKline by 23.7% in the fourth quarter. Two Sigma Investments LP now owns 2,388,168 shares of the pharmaceutical company’s stock valued at $84,708,000 after purchasing an additional 457,276 shares during the last quarter. 11.05% of the stock is currently owned by institutional investors.
NYSE GSK opened at $39.92 on Friday. The company has a current ratio of 0.61, a quick ratio of 0.40 and a debt-to-equity ratio of 3.90. The firm has a market capitalization of $99.72 billion, a PE ratio of 13.63, a price-to-earnings-growth ratio of 2.07 and a beta of 0.82.
GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, April 25th. The pharmaceutical company reported $0.68 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.70 by ($0.02). The company had revenue of $10.04 billion for the quarter, compared to the consensus estimate of $10.26 billion. GlaxoSmithKline had a net margin of 3.50% and a return on equity of 144.84%. equities research analysts anticipate that GlaxoSmithKline will post 2.95 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 12th. Stockholders of record on Friday, May 11th will be given a $0.5298 dividend. This represents a $2.12 annualized dividend and a dividend yield of 5.31%. The ex-dividend date is Thursday, May 10th. GlaxoSmithKline’s dividend payout ratio is currently 89.93%.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.